In this regard, our study demonstrated that the OATP1A2 inhibitor naringin and the unspecific OCT inhibitor MPP reduced the cellular uptake, and in turn, the cytotoxicity of doxorubicin in OATP1A2-overexpressing cells and breast cancer cell lines, respectively. This evidence concerns the gene SLCO1A2 and breast carcinoma.